Cardiovascular emergencies account for 30–40% of an acute medical workload that has grown inexorably over the last two decades. The same period has also witnessed unprecedented changes in the classification, investigation and treatment of acute cardiac problems, driven by advances in basic sciences, pharmacology and technology, but above all by a proliferating body of evidence from controlled trials.